Voreloxin. DNA-intercalating drug topoisomerase II inhibitor oncolytic

H. Moualla, D. A. Mills, R. Hromas, C. F. Verschraegen

Resultado de la investigación: Review articlerevisión exhaustiva

3 Citas (Scopus)


(Chemical Equation Presented) Voreloxin (SNS-595) is being developed by Sunesis Pharmaceuticals under license from Dainippon Sumitomo Pharma for the treatment of a variety of solid and hematological malignancies. Voreloxin is a naphthyridine derivative that acts partly by inhibition of topoisomerase II, causing replication-dependent DNA damage in the S-phase of the cell cycle and leading to apoptosis via irreversible G2 arrest. The drug has activity as monotherapy in recurrent acute myelogenous leukemia (AML) and in platinum-refractory ovarian cancer. The predominant dose-limiting toxicity is neutropenia. Voreloxin is now being tested in combination with other cytotoxic agents in patients with AML.

Idioma originalEnglish (US)
Páginas (desde-hasta)363-374
Número de páginas12
PublicaciónDrugs of the Future
EstadoPublished - may. 1 2009
Publicado de forma externa

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Profundice en los temas de investigación de 'Voreloxin. DNA-intercalating drug topoisomerase II inhibitor oncolytic'. En conjunto forman una huella única.

Citar esto